Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05333055 · ClinicalTrials.gov registry record
Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema
A clinical trial, sponsored by Greater Houston Retina Research.
- Terminated
- Registry status
- 107
- Enrollment target
NCT05333055: Clinical Trial study, sponsored by Greater Houston Retina Research.
NCT05333055 is a clinical trial that was terminated before completion, run by Greater Houston Retina Research. The registered enrollment target is 107 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05333055 was terminated before completion, sponsored by Greater Houston Retina Research.
- TERMINATED
- Registry status
- 107 participants
- Enrollment target
Study Summary
The DRAGONS study is a non-interventional, prospective study that will 1. characterize disease state biomarker (including cytokines, KKS metabolites, and cell adhesion molecules) levels from aqueous humor of subjects with various stages of diabetic retinopathy (DR) and diabetic macular edema (DME) as well as other retinal pathologies, and 2. correlate a broad array of aqueous humor disease state biomarkers with DR severity, DME anti-vascular endothelial growth factor (VEGF) responsiveness, and other retinal pathologies.
Primary Outcome
Aqueous humor levels of cytokines, KKS metabolites, and cell adhesion molecules of subjects with various stages of diabetic retinopathy and diabetic macular edema as well as other retinal pathologies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2022-02-10 |
| Est. Completion | 2024-05-15 |
Why NCT05333055 stopped before completion
NCT05333055 is an observational study that tracks outcomes without assigning an intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05333055 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05333055 about?
NCT05333055 is a clinical study titled "Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema". The DRAGONS study is a non-interventional, prospective study that will 1. characterize disease state biomarker (including cytokines, KKS metabolites, and cell adhesion molecules) levels from aqueous humor of subjects with various stages of diabetic retinopathy (DR) and diabetic macular edema (DME) ...
What is the current status of trial NCT05333055?
This trial is currently terminated. The enrollment target is 107 participants. The study started on 2022-02-10. Estimated completion is 2024-05-15.
Who is sponsoring clinical trial NCT05333055?
This trial is sponsored by Greater Houston Retina Research, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491668 · 107 participants
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI